Back

Michael A Vogelbaum

Michael A Vogelbaum is a neurosurgeon at Cleveland Clinic.[12]

He is principal investigator and co-investigator of a broad range of early phase investigator-initiated therapeutic trials, and both national and international multisite collaborative studies.[3]After completing his M.D. and Ph.D. at the University of Virginia, Vogelbaum undertook a residency in neurological surgery at Barnes-Jewish Hospital, where he also served for a year as chief resident in Neurological Surgery.[3]He has spent almost two decades at Cleveland Clinic Foundation, where he is a world-renowned expert in the diagnosis and treatment of benign and malignant tumors of the brain and spinal cord.[3]He has received support and funding from the American Cancer Society, the National Institutes of Health and the Wolf Family Foundation.[3]He has formulated and led multiple single-center and multicenter clinical trials aimed at finding new therapies for glioblastoma and other forms of brain cancer.[4]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Michael A Vogelbaum on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Cleveland Clinic

Employer

  • 2

    Events

  • 151

    Mentions

  • 40

    Docs

Recent events

MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

Dr. Lathia, Dr. Michael Vogelbaum and colleagues previously reported on findings that GBM patients had higher levels of immune suppressive myeloid-derived suppressor cells in the tumor microenvironment and they tended to be resistant to and dependent on macrophage migration inhibitory factor.[6]

06/25/2020

Event Date

Brain Cancer Treatment Utilizes Tumor-Killing Virus, Almost Doubles Survival Time Of Cancer Patients

Researchers have developed an experimental brain cancer treatment that uses a tumor-killing virus called Toca 511 to destroy cancer cells. The treatment involves injecting Toca 511 into cancer patients, where it then infects actively dividing cancer cells and gives them a gene for an enzyme called cytosine deaminase. "The collective results from this virus study, include encouraging survival and excellent safety data, support the ongoing randomized phase 2/3 trial called Toca 5, and offer hope for a new treatment option for patients with brain cancer," Vogelbaum said.[52]

06/02/2016

Event Date